[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369109-105":59,"doc-detail-369109-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-known-genetic-variants-of-brca1-brca2-and-nod2-in-pancreatitis-and-pancreatic-cancer-risk-assessment-research","The known genetic variants of BRCA1, BRCA2 and NOD2 in pancreatitis and pancreatic cancer risk assessment - Research","","Study evaluates whether specific single nucleotide polymorphisms in NOD2 and the cancer-risk genes BRCA1 and BRCA2 contribute to susceptibility to pancreatitis and pancreatic cancer. Genotypes for NOD2 rs2066847, BRCA1 rs80357914, and BRCA2 rs276174813 were analyzed in 553 pancreatitis patients, 83 pancreatic cancer patients, 44 with other pancreatic diseases, and 116 healthy volunteers. Results show a statistically significant, three-fold higher pancreatic cancer risk in carriers of rs2066847 (OR=2.77, p=0.019), while BRCA1/BRCA2 studied variants were not detected. Adjacent polymorphisms appeared only in pancreatic disease patients, suggesting NOD2 as a genetic risk factor.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-known-genetic-variants-of-brca1-brca2-and-nod2-in-pancreatitis-and-pancreatic-cancer-risk-assessment-research/369109/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-known-genetic-variants-of-brca1-brca2-and-nod2-in-pancreatitis-and-pancreatic-cancer-risk-assessment-research/369109.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which genetic variants were analyzed in the study?","Question",{"text":113,"@type":114},"The study genotyped NOD2 rs2066847, BRCA1 rs80357914, and BRCA2 rs276174813 in patients and controls.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What did the study find about NOD2 rs2066847?",{"text":118,"@type":114},"Patients with the rs2066847 polymorphism showed a statistically significant three-fold increased risk of pancreatic cancer (OR=2.77, p=0.019).",{"name":120,"@type":111,"acceptedAnswer":121},"Were BRCA1 and BRCA2 polymorphisms associated with pancreatic cancer in this analysis?",{"text":122,"@type":114},"The studied BRCA1 and BRCA2 polymorphisms were not found in the cohort; however, adjacent polymorphisms were detected only among patients with pancreatic diseases.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369109,1790216055,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe known genetic variants of BRCA1, BRCA2 and NOD2 in pancreatitis and pancreatic cancer risk assessment  \nJarosław Matykiewicz, Wioletta Adamus-Białek􀀍, Monika Wawszczak-Kasza, Bartosz Molasy, Magdalena Kołomańska, Rusłan Oblap, Łukasz Madej, Dorota Kozieł & Stanisław Głuszek  \nThe single nucleotide polymorphism in NOD2 (rs2066847) is associated with conditions that may predispose to the development of gastrointestinal disorders, as well as the known BRCA1 and BRCA2 variants classified as risk factors in many cancers. In our study, we analyzed these variants ina group of patients with pancreatitis and pancreatic cancer to clarify their role in pancreatic disease development. The DNA was isolated from whole blood samples of 553 patients with pancreatitis, 83 patients with pancreatic cancer, 44 cases of other pancreatic diseases, and 116 healthy volunteers. The NOD2 (rs2066847), BRCA1 (rs80357914) and BRCA2 (rs276174813) were genotyped. The statistically significant 3-fold increased risk of pancreatic cancer was detected among the patients with rs2066847 polymorphism (OR = 2.77, p-value = 0.019). We did not find the studied polymorphisms in BRCA1 (rs80357914) and BRCA2 (rs276174813) . However, the adjacent polymorphisms have been detected only in patients with pancreatic diseases. The studied variant in NOD2 occurs more frequently in pancreatic patients and significantly increases the risk of pancreatic cancer. It can be considered as a genetic risk factor that predisposes to cancer development. The analyzed regions in BRCA1 and BRCA2 may be a potential target in further search for a genetic marker of pancreatic diseases.  \nKeywords BRCA1, BRCA2, NOD2, Pancreatitis, Pancreatic cancer  \nPancreatitis, regardless of whether it is acute or chronic, always carries the risk of malignant transformation leading to the development of one of the most dangerous and most difficult to treat and diagnose cancers: pancreatic cancer1–3. Genetic background plays an important role here, but as is widely known, many genes are involved in the metabolic pathways of the pancreas. The search for genetic markers differentiating patients with pancreatic cancer or pancreatitis would be a huge achievement in advancing the development of personalized therapies and prevention regimens against the development of these diseases4,5. Significant progress in oncological treatment was made after the development of modern diagnostics and the introduction of molecular drugs acting specifically against the molecular change in the cancer cell6–8. The recent development of precision medicine is crucial because, based on extensive data on epidemiology, clinical parameters, family history, and genetic analyses, it can propose various strategic models for a given pancreatic disease9. An association between germline single nucleotide variants (SNV) of many genes and an increased risk of pancreatic cancer or pancreatitis has already been proven10–13. However, no clear differences have yet been identified because the same variants are often involved in different pathomechanisms of pancreatic diseases. Additionally, the influence of hereditary susceptibility to pancreatic cancer is enhanced by environmental factors such as smoking or alcohol consumption, which favors the formation of pathogenic somatic mutations leading to the development of cancer14. The literature often identifies germline mutations of many genes that increase the risk of pancreatitis or pancreatic cancer15–17. This entails an increased risk of loss of heterozygosity or loss of function in somatic cells (mostly in the KRAS, CDKN2A, TP53 and SMAD4/DPC4) often identified at different stages ofthe pancreatic cancer development18–22. Germline BRCA1/2 mutations occur in 4–7% of pancreatic cancers and they are the most common mutated genes in familial pancreatic cancer, however, mutations in BRCA2 are more common (5–17% of pancreat","cbCaiofP5zg5CNjE","https://ap.wps.com/l/cbCaiofP5zg5CNjE","pdf",2034630,11,"English","# Study background\n## Genetic markers and precision medicine\n## Hereditary susceptibility and environmental influences\n# Study design and genotyping\n## Patient cohorts\n## SNPs assessed\n# Results and risk association\n## NOD2 rs2066847 and pancreatic cancer\n## BRCA1/BRCA2 findings\n# Interpretation and implications\n## Potential targets for genetic markers\n## Need for larger validation studies","[{\"question\":\"Which genetic variants were analyzed in the study?\",\"answer\":\"The study genotyped NOD2 rs2066847, BRCA1 rs80357914, and BRCA2 rs276174813 in patients and controls.\"},{\"question\":\"What did the study find about NOD2 rs2066847?\",\"answer\":\"Patients with the rs2066847 polymorphism showed a statistically significant three-fold increased risk of pancreatic cancer (OR=2.77, p=0.019).\"},{\"question\":\"Were BRCA1 and BRCA2 polymorphisms associated with pancreatic cancer in this analysis?\",\"answer\":\"The studied BRCA1 and BRCA2 polymorphisms were not found in the cohort; however, adjacent polymorphisms were detected only among patients with pancreatic diseases.\"}]","The known genetic variants of BRCA1, BRCA2 and NOD2 in pancreatitis and pancreatic cancer risk assessment - Research | PDF",1790180798,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1190ece699cf76d0f161ece897996951.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b3d0eed556b380bb26a3d24aaee9f7a.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ca502259d5fc197af75ba86323abe01.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e34d9faa41af69c34dcf783fcde70c8c.webp",980,1287]